Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Mudasir A. Kumar,
Sana Khurshid Baba,
Inamu Rashid Khan,
Mohd Shahnawaz Khan,
Fohad Mabood Husain,
Saheem Ahmad,
Mohammad Haris,
Mayank Singh,
Ammira S. Al‐Shabeeb Akil,
Muzafar A. Macha,
Ajaz A. Bhat
Affiliations
Mudasir A. Kumar
Watson‐Crick Centre for Molecular Medicine Islamic University of Science and Technology Kashmir India
Sana Khurshid Baba
Watson‐Crick Centre for Molecular Medicine Islamic University of Science and Technology Kashmir India
Inamu Rashid Khan
Department of Zoology School of Life Sciences Central University of Kashmir Ganderbal India
Mohd Shahnawaz Khan
Department of Biochemistry College of Sciences King Saud University Riyadh Saudi Arabia
Fohad Mabood Husain
Department of Food Science and Nutrition College of Food and Agriculture Sciences King Saud University Riyadh Saudi Arabia
Saheem Ahmad
Department of Medical Laboratory Sciences College of Applied Medical Sciences University of Hail Hail City Saudi Arabia
Mohammad Haris
Center for Advanced Metabolic Imaging in Precision Medicine Department of Radiology Perelman School of Medicine University of Pennsylvania Philadelphia USA
Mayank Singh
Department of Medical Oncology (Lab.) Dr. BRAIRCH All India Institute of Medical Sciences (AIIMS) New Delhi India
Ammira S. Al‐Shabeeb Akil
Department of Human Genetics‐Precision Medicine in Diabetes Obesity and Cancer Program, Sidra Medicine Doha Qatar
Muzafar A. Macha
Watson‐Crick Centre for Molecular Medicine Islamic University of Science and Technology Kashmir India
Ajaz A. Bhat
Department of Human Genetics‐Precision Medicine in Diabetes Obesity and Cancer Program, Sidra Medicine Doha Qatar
ABSTRACT Glutaminolysis, the metabolic process of converting glutamine into key intermediates, plays an essential role in cellular energy production, signaling, biosynthesis, and redox balance. Deregulation of glutamine metabolism significantly influences various pathological conditions, including cancers and metabolic and neurological diseases. Emerging evidence shows that long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), and oncogenic alterations in glutamine transporters and enzymes enhance glutamine's role as an alternative energy source, supporting cell survival and proliferation under nutrient and oxygen deprivation conditions. To combat the pathogenic effects of altered glutamine metabolism, researchers are developing targeted inhibitors of key enzymes and transporters involved in glutaminolysis. By interfering with the mechanisms that support the growth of cancer cells, these inhibitors may be able to stop the growth of tumors and treat metabolic and neurological conditions. This review provides a comprehensive overview of existing inhibitors and ongoing clinical trials targeting glutamine metabolism, focusing on its potential as a cancer therapeutic strategy. Additionally, the role of lncRNAs and circRNAs in regulating glutamine metabolism is explored, revealing novel avenues for therapeutic intervention in cancer and other diseases.